

Oncogene Inhibitors Therapy Market & Pipeline Insight 2015

<https://marketpublishers.com/r/OAB903745D7EN.html>

Date: April 2015

Pages: 500

Price: US\$ 2,400.00 (Single User License)

ID: OAB903745D7EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Oncogenomics is an emerging field that involves screening of genes that may be involved in cancer development. Human genome consists of 23 chromosomal pairs, approximately 20,000- 25,000 genes and 3,234.83 Mb genome size. Oncogene addiction is a phenomenon in which cancer could be checked by deactivating single oncogene. Proto-onco genes are main target of investigators because they may convert into oncogenes at any stage of life. Sequence level similarity and identification of genetic factors are expected to shed more light on their working. It will allow the investigators to develop drugs capable of preventing oncogene activation and activity in the body. Development of such therapeutics is a daunting task because human genome is quite big and consists of variety of genes whose function has yet to be determined by investigators.

Oncogene Inhibitor market is a rapidly growing segment with numerous products at different stages of clinical pipeline and marketed products at different phases of industry life cycle. Pharmaceutical companies are trying to provide efficient medical care to patients and generate significant revenues by their sales. Large patient base and superior technology are some important factors responsible for continuous growth of this market segment across the globe. Several competitors are available for wide range of malignancies which further makes it imperative for them to provide both therapeutic and financial benefit to the patients. Due to which large numbers of pharmaceutical companies are expected to improve their products to achieve higher sales.

Significant investments in research and development segment could also be attributed as the main reason behind its growth. As a result, several innovative products are under

investigation which would be introduced in market after passing pre described clinical end points and criteria's set by regulatory authorities. Researchers are trying to develop new formulations to have better safety and efficacy profiles along with minimized side effects. Number of oncogene inhibitor for treatment of different malignancies is increasing every year due to which their market shares are expected to increase several folds in coming years. Escalating competition could be considered as one of the biggest driver for oncogene inhibitor therapeutics because this segment has significantly large number of products.

Different oncogene inhibitors have been successfully commercialized by different pharmaceutical companies in past few decades. Oncogenes like c-met and c-myc are one of the most commonly used targets for inhibitors due their involvement in various cancers. This biological phenomenon has given rise to therapeutics which could be commercialized for different cancer categories. In this way, more revenues could be generated and competition could be offered to other cancer therapeutics due to superior therapeutic efficacy. Ras gene was one of the earliest oncogene identified by investigators known to have proto-oncogenic in nature. However, therapeutic for this gene not available in market due to its complex protein structure that is impregnable by oncogenic inhibitors.

'Oncogene Inhibitors Market & Pipeline Insight 2015' Report Highlight:

Global Oncogene Inhibitors Market Overview

Oncogene Inhibitors Pipeline by Company, Indication & Phase

Oncogene Inhibitors Pipeline: 185 Drugs

Majority Oncogene Inhibitors in Preclinical Phase: 105 Drugs

Proto Oncogene Protein c met Inhibitors Pipeline: 42 Drugs

Proto Oncogene Protein c-akt Inhibitors: 39 Drugs

Marketed Oncogene Inhibitors: 22 Drugs

Marketed Proto-Oncogene Protein c-bcl-2 Inhibitors: 8 Drugs

Contents

1. INTRODUCTION TO ONCOGENE INHIBITORS

2. MECHANISM OF ONCOGENE INHIBITORS

3. GLOBAL ONCOGENE INHIBITORS MARKET OVERVIEW

3.1 Current Market Scenario

3.2 Oncogene Inhibitors Clinical Pipeline Insight

4. GLOBAL ONCOGENE INHIBITOR MARKET DYNAMICS

4.1 Favorable Market Parameters

4.2 Commercialization Challenges

5. GLOBAL ONCOGENE INHIBITOR MARKET FUTURE PROSPECTS

6. ONCOGENE PROTEIN INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

6.1 Preclinical

6.2 Suspended & Discontinued

7. PROTO-ONCOGENE PROTEIN C-BCL-2 INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

7.1 Research till Preregistration

7.2 Marketed Drug Clinical Insight

7.3 Suspended & Discontinued

8. PROTO ONCOGENE PROTEIN B RAF INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

8.1 Research till Phase-III

8.2 Marketed Drug Clinical Insight

8.3 Suspended & Discontinued

9. PROTO ONCOGENE PROTEIN C-KIT INHIBITORS PIPELINE BY COMPANY,

INDICATION & PHASE

- 9.1 Research till Preregistration
- 9.2 Marketed Drug Clinical Insight
- 9.3 Suspended & Discontinued

10. PROTO-ONCOGENE PROTEIN C-REL INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

- 10.1 Research

11. PROTO ONCOGENE PROTEIN C-AKT INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

- 11.1 Preclinical till Phase-III
- 11.2 Suspended & Discontinued

12. PROTO ONCOGENE PROTEIN C MET INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

- 12.1 Preclinical till Phase-III
- 12.2 Marketed Drug Clinical Insight
- 12.3 Suspended & Discontinued

13. PROTO ONCOGENE PROTEIN C RET INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

- 13.1 Preclinical till Phase-III
- 13.2 Marketed Drug Clinical Insight
- 13.3 Suspended & Discontinued

14. PROTO-ONCOGENE PROTEIN C MDM2 INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

- 14.1 Preclinical till Phase-I/II
- 14.2 Suspended & Discontinued

15. PROTO-ONCOGENE PROTEIN INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

15.1 Preclinical

16. PROTO-ONCOGENE-PROTEIN-C-ETS INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

16.1 Preclinical

17. PROTO-ONCOGENE PROTEIN C-FLI-1 INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

17.1 Preclinical

18. PROTO ONCOGENE PROTEINS C PIM 1 INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

18.1 Preclinical till Phase-I/II

18.2 Suspended & Discontinued

19. PROTO ONCOGENE PROTEIN C-MYC INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

19.1 Preclinical till Phase-I/II

19.2 Marketed Drug Clinical Insight

20. PROTO ONCOGENE PROTEINS C RAF INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

20.1 Suspended & Discontinued

21. PROTO ONCOGENE PROTEINS C MYB INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

22. MULTIPLE ONCOGENE INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

22.1 Preclinical till Registered

22.2 Marketed Drug Clinical Insight

22.3 Suspended & Discontinued

23. COMPETITIVE LANDSCAPE

- 23.1 AstraZeneca
- 23.2 ArQule Inc
- 23.3 Biogen Idec
- 23.4 Boehringer Ingelheim
- 23.5 Celgene Corporation
- 23.6 Constellation Pharmaceutical
- 23.7 Epizyme Pharmaceutical
- 23.8 Genentech
- 23.9 GalaxoSmithKline
- 23.10 Incyte Corporation
- 23.11 Johnson & Johnson
- 23.12 Merck
- 23.13 Novartis
- 23.14 Onyx pharmaceuticals
- 23.15 Pfizer

List Of Figures

LIST OF FIGURES

Figure 1-1: Features of Oncogenes

Figure 1-2: Types of Genes

Figure 1-3: Factors Responsible for Conversion of Proto-Oncogenes to Oncogenes

Figure 2-1: Activation of Proto-Oncogenes to Oncogenes

Figure 2-2: Benefits of Oncogene Inhibitors

Figure 2-3: Mechanism of Crizotinib

Figure 2-4: Mechanism of Vemurafenib

Figure 2-5: Mechanism of Vorinostat

Figure 3-1: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015

Figure 3-2: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015

Figure 3-3: Discontinued Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015

Figure 3-4: Discontinued Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015

Figure 3-5: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(%), 2015

Figure 3-6: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(Number), 2015

Figure 3-7: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015

Figure 3-8: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015

Figure 3-9: Discontinued Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015

Figure 3-10: Discontinued Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015

Figure 3-11: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015

Figure 3-12: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015

Figure 3-13: Discontinued Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015

Figure 3-14: Discontinued Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015

Figure 3-15: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015

Figure 3-16: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015

Figure 3-17: Discontinued Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015

Figure 3-18: Discontinued Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015

Figure 3-19: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(%), 2015

Figure 3-20: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(Number), 2015

Figure 3-21: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015

Figure 3-22: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015

Figure 3-23: Discontinued Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015

Figure 3-24: Discontinued Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015

Figure 3-25: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(%), 2015

Figure 3-26: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(Number), 2015

Figure 3-27: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(%), 2015

Figure 3-28: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(Number), 2015

Figure 3-29: Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015

Figure 3-30: Multiple Oncogene Inhibitors Pipeline by Phase(number), 2015

Figure 3-31: Discontinued Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015

Figure 3-32: : Discontinued Multiple Oncogene Inhibitors Pipeline by Phase(Number), 2015

Figure 4-1: Oncogene Inhibitor Market Favorable Parameters

Figure 4-2: Commercialization Challenges to Oncogene Inhibitors

List Of Tables

LIST OF TABLES

Table 3-1: Oncogene Inhibitors Pipeline & Marketed Drugs by Segment

COMPANIES

AstraZeneca, ArQule Inc, Biogen Idec, Boehringer Ingelheim, Celgene Corporation, Constellation Pharmaceutical, Epizyme Pharmaceutical, Genentech, GalaxoSmithKline, Incyte Corporation, Johnson & Johnson, Merck, Novartis, Onyx pharmaceuticals, Pfizer

I would like to order

Product name: Oncogene Inhibitors Therapy Market & Pipeline Insight 2015

Product link: <https://marketpublishers.com/r/OAB903745D7EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OAB903745D7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970